CTLA4 and melanoma: Recently, similar results were obtained by Alimohammadi et al. in a murine B16 large established melanoma model where anti-CTLA-4 encapsulated in PEGylated liposomes improved its therapeutic effect compared to the non-liposomal anti-CTLA-4, because nanocarrier delivery allowed a marked Ab accumulation in tumor and a prolonged half-life in blood.